Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Medical Research PC

Neither a doctor nor a teaching hospital

Research payments

$877,645

170 payments

Through program year 2025, Advanced Medical Research PC is reported as receiving $877,645 in research payments, across 170 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $237,048 45
2024 Research $280,992 33
2023 Research $55,606 25
2022 Research $47,784 15
2021 Research $196,977 28
2020 Research $26,206 11
2019 Research $33,031 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $324,268 15 payments
  2. Incyte Corporation $166,607 62 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $161,737 20 payments
  4. Sanofi US Services Inc. $109,723 16 payments
  5. Pfizer Inc. $64,230 19 payments
  6. LEO Pharma AS $22,397 6 payments
  7. Janssen Research & Development, LLC $13,062 8 payments
  8. Arcutis Biotherapeutics, Inc. $6,650 8 payments
  9. Eli Lilly and Company $3,154 5 payments
  10. Dermira, Inc. $3,025 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Interchangeability Study - ABP 654 $119,118 1 payment
  2. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $112,642 12 payments
  3. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $80,644 1 payment
  4. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $70,049 17 payments
  5. ASCEND P3 AD Extension $61,597 2 payments
  6. A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa $52,054 2 payments
  7. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $41,096 7 payments
  8. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $40,731 20 payments
  9. An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis $37,304 8 payments
  10. A Phase 2A Multicenter Randomized Doubleblind Placebocontrolled 16Week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate to Severe Hidradenitis Suppurativa $29,869 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record